NASDAQ
Total Transactions
41
14 buys /27 sells
Shares Acquired
633,188
Transactions: 14•Avg: 45,227.71
Shares Disposed
1,714,597
Transactions: 27•Avg: 63,503.59
Net Activity
-1,081,409
Net Selling•Ratio: 51.85%
Q4 2025(Current) | 633,188 | 1,714,597 | -1,081,409 | 51.85% |
Q2 2025 | 76,227 | 140,682 | -64,455 | 50.00% |
Q1 2025 | 3,087,470 | 2,159,574 | +927,896 | 87.88% |
Q4 2024 | 5,000 | 5,248 | -248 | 50.00% |
Q3 2024 | 0 | 26,922 | -26,922 | 0.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Distribution: 1,081,409 shares•Acquired/Disposed Ratio: 51.85%
Net Activity | |||||
|---|---|---|---|---|---|
BS BENZENO SHARON | Officer: chief commercial ofc imm med | 28 | 798,074 | 1,165,911 | -367,837 |
BS BOBULSKY SUSAN | Officer: chief commercial officer, mrd | 3 | 300,000 | 26,023 | +273,977 |
LF LO FRANCIS | Officer: chief people officer | 4 | 250,000 | 20,875 | +229,125 |
RCM ROBINS CHAD M | Director, officer: ceo and chairman | 16 | 887,304 | 1,039,942 | -152,638 |
RHS ROBINS HARLAN S | Officer: chief scientific officer | 12 | 425,110 | 284,088 | +141,022 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-12-10 | Director | Sale | 22,968 | $16 | $367,488 | 46,722 | |
2025-12-04 | Officer: chief commercial ofc imm med | Purchase | 4,157 | $3.99 | $16,586.43 | 309,395 | |
2025-12-04 | Officer: chief commercial ofc imm med | Purchase | 4,157 | $8.46 | $35,168.22 | 305,238 | |
2025-12-04 | Officer: chief commercial ofc imm med | Purchase | 4,290 | $12.14 | $52,080.6 | 301,081 | |
2025-12-04 | Officer: chief commercial ofc imm med | Sale | 12,604 | $16.85 | $212,377.4 | 296,791 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
HR HERSHBERG ROBERT | Director | Dec 12, 2025 | |
BS BENZENO SHARON | Officer: chief commercial ofc imm med | Dec 8, 2025 | |
BS BENZENO SHARON | Officer: chief commercial ofc imm med | Dec 8, 2025 | |
BS BENZENO SHARON | Officer: chief commercial ofc imm med | Dec 8, 2025 | |
BS BENZENO SHARON | Officer: chief commercial ofc imm med | Dec 8, 2025 |
Net change in shares shown on right
No price data available for this timeframe.